DNA LAB

What DNA LAB does

DNA Laboratories Sdn Bhd (DNA LAB) is a B2B molecular diagnostics laboratory headquartered in Petaling Jaya, Selangor, Malaysia, and a subsidiary of LifeStrands Genomics, which also operates in Singapore and Australia. Founded in 2007, the company has provided over 18 years of molecular and genomic testing services to healthcare providers nationwide — including obstetricians, gynaecologists, paediatricians, clinical oncologists, GP clinics, and hospitals. In 2013, DNA LAB became the first laboratory in Malaysia to introduce Non-Invasive Prenatal Testing (NIPT), establishing a first-mover position that the company still emphasizes in its positioning.

The company's technology stack is built around Next-Generation Sequencing (NGS) combined with proprietary bioinformatics algorithms. Its test portfolio spans the full reproductive and adult genomics continuum: NICC® and NICC® Extended for NIPT and 92 microdeletion/duplication syndromes; CarrierCheck V2 screening over 2,000 genes; Whole Genome Sequencing (30X) and Whole Exome Sequencing (100X); CNGnome® for low-pass CNV detection; CardioStrands (254-gene panel); ThalaCheck® for alpha- and beta-thalassaemia; OncoStrands® comprehensive genomic profiling (523 genes) for oncology; plus PGT-A/PGT-M, HPV genotyping, STI PCR panels, and paternity testing. Quality credentials include CAP accreditation and MS ISO 15189:2022, with participation in six external quality assessment schemes (UK NEQAS, GenQA, QCMD, CAP PT, Minerva Biolabs, Aglae).

DNA LAB's commercial model is direct enterprise sales to clinicians and healthcare institutions — tests are requisitioned exclusively through certified practitioners, with no direct-to-consumer channel. Domestic clients (clinics and hospitals) are invoiced on the last day of each calendar month; overseas customers must pay in full before processing. Pricing is not publicly disclosed. Marketing is primarily digital (website, Instagram, Facebook, LinkedIn) with a small in-house customer care team handling inbound enquiries. Revenue, funding, and management details are not disclosed in available source material.

Name

DNA LAB

Legal name

DNA Laboratories Sdn Bhd

Website

https://dna-laboratories.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

DNA Laboratories Sdn Bhd is a CAP and ISO 15189-accredited molecular diagnostics laboratory in Malaysia, providing NGS-based genetic testing across fertility, prenatal, women's health, germline genomics, and oncology to healthcare providers as a subsidiary of LifeStrands Genomics.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics & Genomic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Molecular diagnostic services
• Prenatal screening tests
• Genomic testing services
• Oncology genomic profiling
• Carrier screening panels

Headquarters

HQ city

Bangi

HQ country

Malaysia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: DNA LAB provides molecular diagnostic and genomic testing services to healthcare providers (clinics, hospitals). Tests are ordered through certified clinicians. The company invoices customers (clinics/hospitals) on the last day of each calendar month. For overseas customers, processing occurs only after full payment is received. Services span fertility/reproductive health, prenatal screening, women's health, germline genomics, oncology, and other genetic tests.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

DNA LAB operates a B2B reference molecular diagnostics laboratory that provides next-generation sequencing (NGS)-based genetic and genomic testing services to certified clinicians and healthcare providers. Its portfolio spans fertility and reproductive health, prenatal screening and diagnostics (including its proprietary NICC® NIPT), women's health, germline genomics, and oncology (OncoStrands® comprehensive genomic profiling). Tests are ordered exclusively through clinicians; the company processes samples at its Petaling Jaya facility and invoices healthcare facilities monthly.

Product overview

DNA LAB offers a comprehensive molecular diagnostics and genomics testing platform serving fertility/reproductive health, prenatal screening, women's health, germline genomics, and oncology. The core offerings include NICC® NIPT (prenatal screening), CarrierCheck V2 (carrier screening), OncoStrands® (cancer genomic profiling), and germline sequencing services (WGS, WES, CNGnome®). These products are supported by specialized panels for cardiovascular health (CardioStrands), thalassaemia (ThalaCheck®), and targeted condition panels (Clinical AnyPanel). The company provides testing from preconception through prenatal and into adulthood, with services including PGT-A/PGT-M for IVF, cervical cancer screening (HPV, LBC), infectious disease testing, and paternity testing.

Differentiator

Problem solved

Functional benefit

Products and services

• NICC® (Non-Invasive ChromosomesCheck) Non-invasive prenatal test (NIPT) that analyses cell-free fetal DNA from maternal blood to screen for chromosomal aneuploidies including Trisomy 21, 18, 13 and sex chromosome abnormalities. Uses advanced NGS with a proprietary fetal DNA fraction enrichment process. Ordered through certified clinicians for pregnant women from 10 weeks gestation.
• NICC® Extended Extended NIPT offering comprehensive coverage of 92 microdeletion/microduplication syndromes (e.g., DiGeorge, Prader-Willi/Angelman) in addition to standard aneuploidy screening, providing broader fetal chromosomal health assessment via NGS.
• CarrierCheck V2 NGS-based genetic carrier screening test that screens over 2,000 genes for autosomal recessive, X-linked recessive, and selected autosomal dominant inherited disorders, including Fragile X syndrome via FMR1 CGG repeat expansion detection. Used by couples planning a family and by fertility specialists.
• Whole Genome Sequencing (WGS) Comprehensive genetic test analysing the entire genome at 30X mean coverage with complete coverage of over 5,400 disease-associated genes, including CNVs ≥3 exons, SNVs in coding and non-coding regions, mitochondrial genome sequencing (5% heteroplasmy), STR expansion screening, and SMA screening via SMN1 copy number analysis.
• Whole Exome Sequencing (WES) Sequencing of protein-coding regions at 100X mean coverage, with enhanced coverage of disease-associated genes and curated deep-intronic variant analysis, reliably detecting CNVs ≥3 exons. Used to diagnose inherited conditions.
• CNGnome® Low-pass whole genome sequencing assay (8x coverage) for reliable detection of copy number variants (CNVs) larger than 25kb, including uniparental disomy detection, offering improved accuracy over traditional karyotyping and microarray.
• CardioStrands Comprehensive genetic testing for inherited cardiovascular conditions including cardiomyopathies, arrhythmias, aortopathies, and familial hypercholesterolemia, with FH Comprehensive Panel (41 genes) and Cardiogenetics Comprehensive Panel (254 genes) using NGS.
• OncoStrands® Comprehensive Genomic Profiling 523-gene hybrid capture NGS panel for solid tumour profiling, detecting SNVs, CNVs, fusions, splice variants, MSI, TMB, and HRD. Covers NCCN biomarkers and FDA-approved targeted therapy genes with clinical trial matching. Includes Essential (50 genes), DNA 68, Extended (109 genes), and Comprehensive (523 genes) panel options for clinical oncologists.
• First Trimester Screening (FTS) Early prenatal screening combining ultrasound nuchal translucency measurement with maternal blood biomarkers (PAPP-A, free β-hCG) to assess risk of Trisomy 21, 18, and 13 between 11-13 weeks gestation, with ~85-90% detection rate for Down syndrome.
• Second Trimester Screening / Double Test (STS) Maternal blood screening between 14-19 weeks measuring AFP and Total hCG to estimate risk of Trisomy 21, Trisomy 18/13, and neural tube defects with ~60-75% detection rate for Trisomy 21.
• ChromosomesCheck™ Rapid genetic test using QF-PCR method to detect common aneuploidies (Trisomy 21, 18, 13, X and Y chromosomes) with faster turnaround time than traditional karyotyping.
• Karyotype Chromosomal analysis examining number and structure of all chromosomes using cell culture technique to detect abnormalities including aneuploidy, translocations, deletions, inversions, triploidy, and mosaicism.
• Haemoglobin Electrophoresis (HbEp) Blood screening test that detects abnormal haemoglobins to identify conditions such as Thalassaemia and sickle cell trait, required prior to Thalassaemia DNA testing.
• ThalaCheck® Alpha (5 del) Genetic test detecting 5 deletions in the alpha-globin gene including –SEA, –FIL, –THAI, -α3.7 and -α4.2 using multiplex GAP-PCR.
• ThalaCheck® Alpha (point mutations) Reflex test using Sanger sequencing to detect point mutations and small deletions/insertions in the HBA2 gene including Hb Adana, Hb Westmead, Hb Quong Sze, and Hb Constant Spring.
• ThalaCheck® Beta Genetic test detecting mutations in the beta-globin gene (HBB) using Sanger sequencing and multiplex GAP-PCR, covering point mutations, small deletions, and the 45kb Filipino deletion.
• Sickle Cell (HbS) and Hemoglobin C (HbC) Test Genetic test for detection of Sickle Cell and Hemoglobin C mutations in the beta-globin gene.
• Spinal Muscular Atrophy (SMA) Testing Genetic test using MLPA technology to detect copy number changes of exons 7 and 8 in SMN1 and SMN2 genes for patient diagnosis and carrier testing.
• HPV DNA Genotyping Molecular test detecting and identifying 28 HPV types (19 high-risk, 9 low-risk) for cervical cancer risk assessment from cervical samples.
• Liquid-Based Cytology (LBC) Modern cervical cancer screening method preserving cells in a liquid solution for clearer, more accurate detection of abnormal or pre-cancerous cells.
• Ovarian Cancer Screening Blood test calculating ovarian cancer risk based on HE4 and CA 125 biomarker concentrations to distinguish between benign and malignant ovarian conditions.
• FemCheck PCR-based diagnostic test detecting common sexually transmitted infections including Chlamydia, Gonorrhoeae, Trichomonas, Ureaplasma species, and Mycoplasma species.
• Infectious Disease (HSV) Real-Time PCR test detecting Herpes Simplex Virus types 1 and 2 (combined) DNA to identify active HSV infection.
• Infectious Disease – Cytomegalovirus (CMV) Real-Time PCR test detecting Cytomegalovirus DNA to indicate active CMV infection, important for pregnant women and immunocompromised individuals.
• EmbryoCheck (PGT-A) NGS-based Preimplantation Genetic Testing for Aneuploidy (PGT-A) screening embryos for chromosomal abnormalities to improve IVF success rates.
• Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) Specialized genetic test customized for couples to detect known single-gene disorders in embryos created through IVF, targeting conditions such as Thalassaemia.
• Anti-Mullerian Hormone (AMH) Test Blood test measuring AMH levels to assess ovarian reserve and estimate remaining egg supply for fertility planning and IVF treatment.
• Y-Chromosome Deletion Molecular genetic test detecting deletions in azoospermia factor (AZF) regions (AZFa, AZFb, AZFc) of the Y chromosome associated with male infertility.
• DNA Paternity/Maternity Test DNA profile comparison using PCR-STR method to determine biological parentage (not designed for legal proceedings).
• Non-Invasive Paternity Test Safe prenatal paternity test comparing fetal DNA from maternal blood with alleged father's DNA using SNP typing, applicable for singleton and twin pregnancies.
• Clinical AnyPanel Targeted gene panels for specific conditions including Hearing Loss, Hereditary Cancer, Metabolic/Mitochondrial Disorders, Neurology, Neuromuscular, Ophthalmology, Cardiology, and Customized Testing.

Quantifiable outcome

• NICC® Extended detects 92 microdeletion/microduplication syndromes
• +3 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability18 records

Feature6 records

Partnerships

One partnership is on record.

• LifeStrands GenomicscoreOthersDNA LAB is a part of LifeStrands Genomics, with operations in Australia, Singapore and Malaysia. LifeStrands Genomics is the parent organization overseeing DNA LAB's operations across three countries.

Scale indicators3 records

Expansion highlights4 records

Broad incumbents

• Sonic Healthcare: Global medical diagnostics provider with extensive operations in Australia, Germany, and the US, and growing presence in Asia. Comparable as a broad incumbent offering genetic and molecular testing as part of a wider laboratory services portfolio, with Australia operations via LifeStrands Genomics context.
• BGI Genomics: China-based global genomics company offering NIPT, NGS, and rare disease testing. Comparable as a large-scale Asian molecular diagnostics provider with broad NGS-based test menus that competes on price and scale in regional markets.
• Natera: US-based specialty molecular diagnostics company with leading NIPT, oncology, and organ transplant testing franchises. Comparable as a pioneer in cell-free DNA-based NIPT technology that DNA LAB's NICC® competes with at the global technology level.

Emerging players

• SOPHiA Genetics: Switzerland-headquartered health technology company providing AI-driven NGS data analysis for oncology and rare disease testing. Comparable to DNA LAB's bioinformatics-driven approach to OncoStrands® and WGS interpretation, with active distribution across Asia-Pacific.
• Healtheon (MyGenetic): Malaysian-based genetic testing provider offering NIPT and hereditary cancer panels. Comparable as a domestic Malaysian molecular diagnostics competitor targeting the same clinician base in the same primary market.
• Genetica (Vietnam): Vietnam and Southeast Asia-focused genetic testing service provider offering NIPT and pharmacogenomics. Comparable as an emerging regional molecular diagnostics player expanding the SEA NIPT and genetic testing market in geographies adjacent to DNA LAB's core.

Direct peers

• Prenetics: Hong Kong-headquartered genetics and molecular diagnostics company operating across Southeast Asia. Directly comparable as a regional NIPT and genomic testing provider targeting similar clinician and consumer channels in the same geographic region.

Regional players

• Innoquest Pathology: Singapore-based clinical reference laboratory offering molecular and genetic testing services. Comparable as a Southeast Asian reference lab serving OBs/GYNs and hospitals with NGS-based panels, operating in a closely adjacent geography.
• Pathology Asia (Innovative Diagnostics): Singapore-based clinical laboratory network providing molecular diagnostics and specialty testing. Comparable to DNA LAB as a regional reference lab serving OBs/GYNs and hospitals with overlapping genetic and prenatal test menus.

Others

• IHH Healthcare (Pantai / Gleneagles): Malaysia-based major private hospital operator running Pantai and Gleneagles facilities. Comparable as the principal hospital customer channel for DNA LAB's B2B reference services and as a key decision-maker on test vendor selection in Malaysian private healthcare.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/DNA.LAB
• LinkedInlinkedin.com/company/dna-laboratories-sdn-bhd
• Instagraminstagram.com/dna.lab
• Xx.com/dnalaboratories

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DNA LAB